Cellnovo is developing and manufacturing an innovative mobile diabetes management system.

Comprised of a mobile connected micro-pump, mobile touchscreen controller, blood glucose meter and software applications, the Cellnovo system provides intuitive operation, wireless Internet connectivity and real-time activity tracking – all industry firsts.

Cellnovo was listed through an IPO on NYSE Euronext in July 2015 and the Fund retains a shareholding.

Headquarters
UK

INVESTMENT DATE
February 2011

INVESTMENT THESIS
Venture-stage investment in medical technology

STATUS
Current

INDUSTRY
Diabetes

STAGE CAPITAL TEAM
Aris Constantinides